Here, we exploited these nasal CRC-derived in vitro models of CF for the characterization of the L1077P CFTR variant and the evaluation of its response to the ETI combination to obtain important inferences for future personalized patient therapy. This evidence concerns the gene CFTR and cystic fibrosis.